Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 16/20 | 0.93 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782854 | 0.88 | KIT (0.93) | KITNPC1POLBRAB9ATDP1 | |
| SCHEMBL17782832 | 0.88 | KIT (0.80) | KITNPC1GAA | |
| SCHEMBL17782812 | 0.86 | KIT (0.71) | KITNPC1POLBRAB9ATDP1 | |
| SCHEMBL17788007 | 0.86 | KIT (0.93) | KITNPC1RAB9AGAAMEN1 | |
| SCHEMBL17788006 | 0.86 | KIT (0.93) | KITGAAMEN1KMT2A | |
| SCHEMBL17782837 | 0.85 | KIT (0.79) | KITGAAMEN1KMT2A | |
| SCHEMBL17782855 | 0.85 | KIT (0.74) | KITNPC1RAB9ATDP1GAA | |
| SCHEMBL17782820 | 0.85 | KIT (0.93) | KITNPC1RAB9AGAAMEN1 | |
| SCHEMBL17782792 | 0.84 | KIT (0.93) | KITGAA | |
| SCHEMBL17782773 | 0.84 | KIT (0.93) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | claimed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | disclosed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | disclosed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | KIT, CHUK, CSNK1E | KIT 1/4885NPC1 3114/4885POLB 2660/4885 |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | KIT, CHUK, CSNK1E | KIT 1/4885NPC1 3114/4885POLB 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.